



Making  
Difficult  
Easier

## Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Codes

### *ICD-10 Codes:*

**XW033C3** - Introduction of Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 3

**XW043C3** - Introduction of Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 3

### *ICD-10 Diagnosis Codes:*

**C91.00** - Acute lymphoblastic leukemia not having achieved remission

**C91.02** - Acute lymphoblastic leukemia, in relapse

**C82.0-C82.99** - Follicular lymphoma

**C83.30-C83.39** - Diffuse large B-cell lymphoma

**C85.20-C85.29** - Mediastinal (thymic) large B-cell lymphoma

**Z51.11** - Encounter for antineoplastic chemotherapy

**Z51.12** - Encounter for antineoplastic immunotherapy

### *Drug Codes:*

**Q2042** - Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose (Kymriah) – new code effective 1-1-19

**Q2041** - Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose (Yescarta)

### *Hospital Billing:*

**REV 87x = 087x Cell/Gene Therapy** - Charges for procedures performed by staff for the acquisition and infusion/injection of genetically modified cells.

**REV 89x = 089x Pharmacy - Extension of 025x and 063x** - 0891 Special Processed Drugs - FDA Approved Cell Therapy(a) DRUGS/CELL THERAPY

### *Procedure Codes for claims submitted on or after April 1, 2019:*

**HCPCS 0537T with revenue code 0871** - Collection/handling

**HCPCS 0538T with revenue code 0872** - Preparation for transport

**HCPCS 0539T with revenue code 0873** - Receipt and preparation